Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Triple Negative Breast Cancer
Interventions: DRUG: Pembrolizumab & ADG106 (Phase Ib)|DRUG: Pembrolizumab & ADG106 (Phase II)
Sponsor: National University Hospital, Singapore
Collaborators: Adagene Inc|Merck Sharp & Dohme LLC